AstraZeneca’s PARP Inhibitor Demonstrates Clinical Benefit in Combo with Novel Hormonal Agent Targeting mCRPC

Recently AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced positive high-level results from the PROpel Phase III trial. LYNPARZA® (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus standard-of-care abiraterone as a 1st-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.

What is Olaparib?

Marketed under the trade name Lynparza, this PARP inhibitor is used as a treatment for the maintenance of BRCA-mutated advanced ovarian cancer in adults. The therapy acts on cancers in people with hereditary BRCA1 or BRCA2 mutations, which associate with some ovarian, breast, and prostate cancers.  This drug already has a  number of approvals.

The Condition

Prostate cancer is the second-most common cancer in men, and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low.

In America, nearly 250,000 new diagnoses are forecast for men in 2021. A number of new the...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee